• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

8 drug delivery innovations you need to know

February 25, 2021 By Sean Whooley

Inovio’s smart vaccine delivery

Image from Inovio

Inovio Pharmaceuticals (NSDQ:INO) last summer picked up a contract from the U.S. government to develop a potential game-changer amid the COVID-19 pandemic.

The U.S. Department of Defense awarded Inovio $71 million to support large-scale manufacturing for the Cellectra 3PSP smart device and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin.

While the late-stage trial for the vaccine candidate is slated for later this year after the FDA put a temporary hold on it in the fall, the delivery method is still one to watch.

The small, portable, hand-held device runs on “AA” batteries and is designed to deliver the INO-4800 vaccine, meant to prompt the body’s immune system to drive an immune response.

Cellectra uses a brief electrical pulse to reversibly open small pores in the cell and allow plasmids to enter, which Inovio says is a limitation of other DNA and other nucleic acid approaches, such as mRNA. Once the DNA plasmids are inside the cell, they enable the cell to produce the targeted antigen, which is processed naturally to trigger the desired T-cell and antibody-mediated immune responses.

Inovio’s delivery system is designed to ensure that DNA medicine is efficiently delivered into the body’s cells to drive an immune response, while the medicines do not interfere with or change an individual’s own DNA in any way.

Next>>

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Hydrogels, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Research & Development, Respiratory, Technology Tagged With: dyvebioscience, Enable Injections, evoxtherapeutics, Inovio Pharmaceuticals, Johns Hopkins, Lyra Therapeutics, Medtronic, Tandem Diabetes Care, Teva, Teva Pharmaceuticals, Teva Respiratory

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS